Metabolite profile of a mouse model of Charcot-Marie-Tooth type 2D neuropathy: implications for disease mechanisms and interventions

被引:6
|
作者
Bais, Preeti [1 ]
Beebe, Kirk [2 ]
Morelli, Kathryn H. [1 ,3 ]
Currie, Meagan E. [1 ]
Norberg, Sara N. [1 ]
Evsikov, Alexei V. [1 ,4 ]
Miers, Kathy E. [1 ]
Seburn, Kevin L. [1 ]
Guergueltcheva, Velina [5 ,9 ]
Kremensky, Ivo [6 ]
Jordanova, Albena [7 ,8 ]
Bult, Carol J. [1 ]
Burgess, Robert W. [1 ,3 ]
机构
[1] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA
[2] Metabolon Inc, Durham, NC 27713 USA
[3] Univ Maine, Grad Sch Biomed Sci & Engn, Orono, ME 04469 USA
[4] Univ S Florida, Dept Mol Med, USF Hlth, Tampa, FL 33620 USA
[5] Med Univ Sofia, Dept Neurol, Sofia 1431, Bulgaria
[6] Med Univ Sofia, Univ Hosp Obstet & Gynecol, Dept Obstet & Gynecol, Natl Genet Lab, Sofia 1431, Bulgaria
[7] Univ Antwerp, VIB Dept Mol Genet, Mol Neurogen Grp, B-2610 Antwerp, Belgium
[8] Med Univ Sofia, Dept Med Chem & Biochem, Mol Med Ctr, Sofia 1431, Bulgaria
[9] Univ Hosp Sofiamed, Sofia 1797, Bulgaria
来源
Biology Open | 2016年 / 5卷 / 07期
基金
美国国家卫生研究院;
关键词
Peripheral neuropathy; Spinal cord; Sciatic nerve; Metabolomics; Mass Spectrometry; tRNA synthetase; TRANSFER-RNA SYNTHETASE; ACETYL-L-CARNITINE; ASCORBIC-ACID TREATMENT; SPINAL MUSCULAR-ATROPHY; ALPHA-LIPOIC ACID; OLD RATS; PERIPHERAL NEUROPATHY; SERINE PALMITOYLTRANSFERASE; MASS-SPECTROMETRY; METABOLOMICS DATA;
D O I
10.1242/bio.019273
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Charcot-Marie-Tooth disease encompasses a genetically heterogeneous class of heritable polyneuropathies that result in axonal degeneration in the peripheral nervous system. Charcot-Marie-Tooth type 2D neuropathy (CMT2D) is caused by dominant mutations in glycyl tRNA synthetase (GARS). Mutations in the mouse Gars gene result in a genetically and phenotypically valid animal model of CMT2D. How mutations in GARS lead to peripheral neuropathy remains controversial. To identify putative disease mechanisms, we compared metabolites isolated from the spinal cord of Gars mutant mice and their littermate controls. A profile of altered metabolites that distinguish the affected and unaffected tissue was determined. Ascorbic acid was decreased fourfold in the spinal cord of CMT2D mice, but was not altered in serum. Carnitine and its derivatives were also significantly reduced in spinal cord tissue of mutant mice, whereas glycine was elevated. Dietary supplementation with acetyl-L-carnitine improved gross motor performance of CMT2D mice, but neither acetyl-L-carnitine nor glycine supplementation altered the parameters directly assessing neuropathy. Other metabolite changes suggestive of liver and kidney dysfunction in the CMT2D mice were validated using clinical blood chemistry. These effects were not secondary to the neuromuscular phenotype, as determined by comparison with another, genetically unrelated mouse strain with similar neuromuscular dysfunction. However, these changes do not seem to be causative or consistent metabolites of CMT2D, because they were not observed in a second mouse Gars allele or in serum samples from CMT2D patients. Therefore, the metabolite 'fingerprint' we have identified for CMT2D improves our understanding of cellular biochemical changes associated with GARS mutations, but identification of efficacious treatment strategies and elucidation of the disease mechanism will require additional studies.
引用
收藏
页码:908 / 920
页数:13
相关论文
共 50 条
  • [21] Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A
    Graf, WD
    Chance, PF
    Lensch, MW
    Eng, LJ
    Lipe, HP
    Thomas, TD
    CANCER, 1996, 77 (07) : 1356 - 1362
  • [22] Electrophysiological trends in Charcot-Marie-Tooth disease type 2
    Jerath, Nivedita
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (04) : 252 - 252
  • [23] Charcot-Marie-Tooth Disease Type 2B
    Durdu, Senay
    Koc, Kadriye
    Balaban, Deniz
    Karaoglu, Aynur
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2009, 43 (02): : 65 - 67
  • [24] A novel transgenic mouse model of Chinese Charcot-Marie-Tooth disease type 2L
    Zhang, Ruxu
    Zhang, Fufeng
    Li, Xiaobo
    Huang, Shunxiang
    Zi, Xiaohong
    Liu, Ting
    Liu, Sanmei
    Li, Xuning
    Xia, Kun
    Pan, Qian
    Tang, Beisha
    NEURAL REGENERATION RESEARCH, 2014, 9 (04) : 413 - 419
  • [25] A CHARCOT-MARIE-TOOTH DISEASE TYPE 2-LIKE NEUROPATHY IN A 49, XXXXY MALE
    King, Staci
    Kushlaf, Hani
    MUSCLE & NERVE, 2015, 52 : S86 - S86
  • [26] Charcot-Marie-Tooth Disease Complicating Type 2 Diabetes
    Win, Htet Htet Ne
    Davenport, Colin
    Delaney, Siobhan
    Kelly, Margaret
    Smith, Diarmuid
    JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION, 2011, 101 (04) : 349 - 352
  • [27] AN AGGRESSIVE DEMYELINATING NEUROPATHY MIMICKING CHARCOT-MARIE-TOOTH DISEASE
    De Grado, Amedeo
    Pisciotta, Chiara
    Benzoni, Chiara
    Salsano, Ettore
    Corbetta, Marinella
    Magri, Stefania
    Taroni, Franco
    Pareyson, Davide
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 : S18 - S18
  • [28] Charcot-Marie-Tooth Disease: Lessons in Genetic Mechanisms
    James R. Lupski
    Molecular Medicine, 1998, 4 : 3 - 11
  • [29] Charcot-Marie-Tooth disease: Lessons in genetic mechanisms
    Lupski, JR
    MOLECULAR MEDICINE, 1998, 4 (01) : 3 - 11
  • [30] A FAMILY WITH TOMACULOUS NEUROPATHY MIMICKING CHARCOT-MARIE-TOOTH DISEASE
    BARBIERI, F
    SANTANGELO, R
    CRISCI, C
    RAGNO, M
    PERRETTI, A
    SANTORO, L
    CLINICAL NEUROLOGY AND NEUROSURGERY, 1990, 92 (03) : 289 - 294